A Potent SARS-CoV-2 Neutralizing Human Monoclonal Antibody That Reduces Viral Burden and Disease Severity in Syrian Hamsters

A Potent SARS-CoV-2 Neutralizing Human Monoclonal Antibody That Reduces Viral Burden and Disease Severity in Syrian Hamsters

The emergence of COVID-19 has led to a pandemic that has caused millions of cases of disease, variable morbidity and hundreds of thousands of deaths. Currently, only remdesivir and dexamethasone have demonstrated limited efficacy, only slightly reducing disease burden, thus novel approaches for clin...

Full description

Bibliographic Details
Main Authors: Anna C. Fagre, John Manhard, Rachel Adams, Miles Eckley, Shijun Zhan, Juliette Lewis, Savannah M. Rocha, Catherine Woods, Karina Kuo, Wuxiang Liao, Lin Li, Adam Corper, Dilip Challa, Emily Mount, Christine Tumanut, Ronald B. Tjalkens, Tawfik Aboellail, Xiaomin Fan, Tony Schountz
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-12-01
Series:Frontiers in Immunology
Subjects:
COVID
monoclonal Ab
SARS-CoV-2
therapeutic antibodies
coronavirus
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2020.614256/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2020.614256/full

Similar Items